April 18, 2026 07:20 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Pushback from smartphone makers: Centre drops Aadhaar app pre-install plan — report | Meta eyes first wave of layoffs on May 20: Report | TCS breaks silence on Nida Khan: ‘No HR role, no power’ in Nashik case | ‘Panic reaction’: Rahul Gandhi on women’s bill, says PM Modi ‘wants to send a message’ | Adani Group shares rise as Gautam Adani becomes Asia’s richest, overtakes Mukesh Ambani | TCS Nashik ‘conversion’ case accused seeks anticipatory bail citing pregnancy | IT raids TMC candidate Debasish Kumar’s premises ahead of Bengal polls | Bengal SIR: Supreme Court allows voters restored by tribunal till April 21 and 27 to vote | 'Women won't spare you': PM Modi warns Opposition over resistance to quota bill | Vijay booked in 3 cases over poll code violation ahead of Tamil Nadu polls
Weight loss
Study finds weight loss causes significant muscle loss. Photo: Unsplash

Losing weight? You might be losing muscle faster than you think

| @indiablooms | Apr 18, 2026, at 05:38 pm

A new UNC School of Medicine study of incretin-based medications, including newer medications such as semaglutide and tirzepatide that are widely prescribed for Type 2 diabetes and obesity, are associated with high rates of muscle loss relative to the amount of weight lost.

John A. Batsis, MD, an expert on obesity and nutrition at the UNC School of Medicine and the UNC Gillings School of Public Health, published his team’s findings in Annals of Internal Medicine.

“While muscle loss is expected during weight loss, we observed that the proportion of weight loss attributable to muscle was consistently higher than anticipated across studies,” said Batsis. “These findings suggest that the magnitude of muscle loss relative to total weight loss warrants closer attention.”

Batsis and his team advise clinicians to carefully monitor patient’s muscle health when advising intentional weight loss.

The findings underscore a need for muscle evaluations and measurements in clinical trials, as well as more trials geared towards older adults taking semaglutide, tirzepatide, and other similar medications.

“Few current studies include participants older than 60 years, and none focused on adults aged 65 years or older,” said Batsis. “Significant muscle loss can lead to a higher fall risk, so additional trials specifically designed to evaluate aging-related outcomes that include mobility and quality of life are urgently needed.”

The findings were presented by Batsis at the breaking news scientific plenary session “New in Annals of Internal Medicine: Hear it First from the Authors” in San Francisco, California, during the American College of Physicians’ (ACP) Internal Medicine Meeting.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.